Tibion Corporation, Moffett Field, California, has appointed Charles Remsberg as its chief executive officer. According to Tibion, Remsberg has nearly 20 years of experience building global and domestic sales for leading high-technology rehab companies.
“The board of directors selected Mr. Remsberg because of his customer-centered focus and experience in commercialization of high-technology rehabilitation systems,” explained Tibion president and cofounder Kern Bhugra. “We believe Mr. Remsberg can best help us rapidly achieve commercialization of Tibion products.”
Remsberg most recently served for three years as CEO of Hocoma, the U.S. sales and marketing arm of the privately held Swiss company Hocoma AG, best known for its clinic-based Lokomat® robotic-gait orthosis. Prior to that position, he was head of worldwide sales for Hocoma, and for more than ten years served as an executive at Biodex Medical Systems, Shirley, New York. At Biodex, he rose from product development manager to head of worldwide sales.
Remsberg commented, “I joined Tibion because I am impressed with the impact its technology can have on the rehabilitation of millions of handicapped patients worldwide. I look forward to the opportunity to accelerate acceptance of the [PK100] Bionic Leg [Orthosis], and the application of its technology to other unmet patient needs.”
John Steuart, a member of the Tibion board of directors, stated, “Tibion has reached the stage where its first product is ready for clinical evaluation and marketing, and follow-on products are in development. We looked for a leader who understood the skills needed to deliver leading-edge equipment, and had the confidence of rehabilitation academia, clinicians and major providers. We are excited by the potential of the company under his leadership.”